Metsera, Inc. (NASDAQ:MTSR – Get Free Report)’s stock price hit a new 52-week low during trading on Tuesday . The stock traded as low as $24.11 and last traded at $24.57, with a volume of 131556 shares changing hands. The stock had previously closed at $25.03.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on MTSR. Cantor Fitzgerald started coverage on shares of Metsera in a report on Tuesday, February 25th. They issued an “overweight” rating on the stock. Evercore ISI began coverage on Metsera in a report on Tuesday, February 25th. They issued an “outperform” rating on the stock. Guggenheim began coverage on Metsera in a research report on Tuesday, February 25th. They set a “buy” rating and a $56.00 price target for the company. Finally, Bank of America initiated coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price objective on the stock.
Get Our Latest Stock Report on Metsera
Metsera Price Performance
Metsera Company Profile
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Read More
- Five stocks we like better than Metsera
- Where to Find Earnings Call Transcripts
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- High Flyers: 3 Natural Gas Stocks for March 2022
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
